The European Medicines Agency (EMA) and the Netherlands have finalised the text of a Seat Agreement which describes how the Agency, its bodies and its employees will be treated by the Dutch once they start operating in the Netherlands.

On Friday, 13 April, the Dutch Council of Ministers agreed to sign the document. The Seat Agreement ensures that EMA can function properly and independently in the Netherlands. This is an important step in the relocation of EMA from London to Amsterdam as a result of Brexit.

The Seat Agreement will enter into force as soon as it is signed by both, EMA and the Netherlands. The signing will take place once the legislative process on the relocation of EMA by the European Council, the European Parliament and the European Commission has been completed.

The Netherlands and EMA are pleased that they have completed the negotiations on this agreement earlier than anticipated.

Source:

EMA